Skip to main content
Premium Trial:

Request an Annual Quote

NIAID Gives UTMB Galveston up to $10.9M for Infectious Disease Biomarker Center

NEW YORK (GenomeWeb News) – The National Institute of Allergy and Infectious Diseases will grant up to $10.9 million to the University of Texas Medical Branch, Galveston, to seek biomarkers for infectious diseases, NIAID said Thursday.
 
UTMB will use the five-year contract to establish the Clinical Proteomics Center for Infectious Disease and Biodefense, one of two such centers funded by NIAID. As reported last week by GenomeWeb Daily News, Caprion Proteomics will receive as much as $12.9 million from NIAID to establish its center and fund research.
 
UTMB researchers will search for proteins that are created by pathogens, or made by the human body in response to infection. These proteins could be used as indicators of disease to develop diagnostics, therapies, or vaccines, Maureen Beanan, NIAID program officer in microbiology and infectious diseases, said in a statement.
 
The first two diseases the centers will study include dengue fever and brucellosis. Any candidate biomarkers will be made publicly available for free to the research community for further development.
 
These centers also will assess samples submitted from outside institutions for protein biomarkers, Beanan added.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.